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Copyright © 2004 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.08.019Objective: Spinal cord ischemia/reperfusion injury involves multiple factors that
may be modulated by adenosine A2A receptor activation. This study defines
injury progression in terms of function, cytoarchitecture, and inflammation and
assesses whether adenosine A2A receptor activation by ATL-146e limits injury
progression.
Methods: Mature swine were divided into 3 groups: sham thoracotomy, IR (30
minutes of ischemia followed by reperfusion), and ATL (ischemia/reperfusion with
ATL-146e administration for the first 3 hours of reperfusion). Subgroups were killed
at 0, 3, 6, 12, 24, and 48 hours after reperfusion. Function was followed up with
Tarlov scores. Spinal cord tissue was evaluated for neuronal viability, micro-
tubule-associated protein–2 immunohistochemistry, and neutrophil sequestra-
tion (myeloperoxidase assay). Spinal cord tissue, cerebrospinal fluid, and serum
were evaluated for tumor necrosis factor- by enzyme-linked immunosorbent
assay.
Results: Function was significantly impaired at 24, 36, and 48 hours in the IR group
compared with the sham and ATL groups (P  .05). Neuronal viability and
microtubule-associated protein–2 staining were significantly preserved in the sham
and ATL groups compared with the IR group at 24 and 48 hours (P  .05). Spinal
cord myeloperoxidase levels were significantly higher in the IR group than in the
sham and ATL groups at 24 and 48 hours. Although negligible in serum and
cerebrospinal fluid, tumor necrosis factor- levels in the spinal cord peaked signif-
icantly higher in the IR group compared with the sham and ATL groups at 6 and 24
hours (P  .05).
Conclusions: Spinal cord ischemia/reperfusion induced changes in neutrophil
sequestration, microtubule-associated protein–2 expression, and neuronal via-
bility within 24 hours of reperfusion. Spinal cord tumor necrosis factor-
increased significantly by 6 to 12 hours after reperfusion. Adenosine A2A
receptor activation attenuates spinal cord inflammation, which may be critical
for the preservation of neuronal function and cytoarchitecture after ischemia/
reperfusion.
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CDParaplegia remains a significant risk for up to20% of patients undergoing thoracic and tho-racoabdominal aortic interventions.1 Al-though neuroprotective strategies for thesepatients are emerging, no pharmacologic in-terventions have been adequate for use in
patients to prevent ischemic spinal cord injury.2
Previous studies have suggested that adenosine A2A re-
ceptor activation may modulate several aspects of spinal
cord ischemia/reperfusion (IR) injury. A2A activation sup-
presses the inflammatory response to traumatic brain injury
by suppressing leukocyte recruitment and by reducing cy-
tokine release, most notably tumor necrosis factor (TNF)-
and interleukin-1. Spinal cord IR injury involves apoptotic
death of neurons and white matter damage after injury,
which can be further exacerbated by secondary inflamma-
tion.3 Adenosine A2A receptor–mediated suppression of in-
flammation may also limit this process of neuronal degen-
eration.
Previous studies using ATL-146e to activate the adeno-
sine A2A receptor in animal models have shown that sys-
temic adenosine A2A receptor activation can prevent func-
tional impairment after temporary aortic occlusion.4-7 Other
studies suggested that adenosine A2A receptor activation
reduced systemic TNF- levels and preserved spinal cord
histology within the first 48 hours.8 However, the progres-
sion of spinal cord IR injury with respect to function, local
and regional inflammation, and cytoarchitecture has not
been examined. Moreover, the effect of adenosine A2A
receptor activation on spinal cord IR injury progression is
not known.
In this study, we evaluated the effect of adenosine A2A
receptor activation on the progression of spinal cord IR
injury in terms of inflammation, neuronal cytoarchitecture,
and function. We attempted to define the progression of
cytoarchitectural damage over the first 48 hours by using
neuronal viability scoring and microtubule-associated
protein–2 (MAP-2) staining, a sensitive marker of ischemic
neuronal injury.9 Additionally, we defined the progression
of the local inflammatory response by focusing on neutro-
phil sequestration and TNF- concentration, not only sys-
temically in serum, but also regionally in cerebrospinal fluid
(CSF) and locally in neuronal tissue. Finally, we observed a
group of treated animals for 1 week after injury to determine
whether the benefit in motor function is preserved over time.
Methods
All protocols were reviewed and approved by the Animal Care and
Use Committee of the University of Virginia before the study
began. All animals received humane care in compliance with the
“Guide for the Care and Use of Laboratory Animals” (Institute of
Laboratory Animal Resources, Commission on Life Sciences, Na-
tional Research Council, 1996).
926 The Journal of Thoracic and Cardiovascular Surgery ● DeceMature domestic swine were separated into 3 groups. Sham,
ATL-treated, and IR control groups underwent the following pro-
cedures before they were killed at specific time points for procure-
ment of serum, CSF, and tissue.
Procedures
Domestic pigs were anesthetized with intramuscular ketamine (50
mg/kg) and xylazine (1 mg/kg). Pigs were intubated before con-
nection to a volume ventilator (respiratory rate of 14 breaths/min
and tidal volume of 250 mL). Anesthesia was maintained with
vaporized halothane. The arterial pressure was monitored with a
pressure transducer (Hewlett-Packard, Palo Alto, Calif). Mainte-
nance fluids were given at 100 mL/h. The animals’ temperatures
were maintained at 36°C for the procedure by using a heating pad.
Through a left lateral thoracotomy, the distal aortic arch and
descending aorta was exposed. After systemic heparinization (hep-
arin sulfate 200 U/kg), a crossclamp was placed on the descending
aorta distal to the left subclavian artery takeoff. The crossclamp
was left in place for 30 minutes before the distal aorta was
reperfused in the IR control animals. After reperfusion and hemo-
stasis, the chest was closed. The animals were then allowed to
emerge from anesthesia. Sham animals underwent the entire pro-
cedure except for the aortic occlusion. ATL-146e–treated animals
(ATL group) underwent the IR procedure in addition to ATL-146e
(0.06 g · kg1 · min1 IV) beginning 10 minutes before reper-
fusion and continuing for 3 hours. This dose of ATL was estab-
lished in previous studies as optimal for ischemic spinal cord
preservation.6
The animals were killed at specific times of reperfusion. Eight
animals in each group at each time point were killed at the onset
of reperfusion (sham and IR only) and then at 3, 6, 12, 24, and 48
hours after reperfusion (n  136). Four more ATL animals were
observed for 7 days to evaluate for any functional decompensation.
Functional Assessment
Functional status was graded by a blinded observer using the
Tarlov scale.10 Scores range from 0 to 5 and are based on hind
limb movement. No hind limb movement meant a score of 0. Some
movement meant a score of 1. Animals able to sit with assistance
were graded as 2. Animals able to sit alone received a score of 3.
Animals with an unsteady gait received a score of 4. Animals with
a normal gait received a score of 5. Functional scores were taken
at 12, 24, 36, and 48 hours. The 7-day survivors were graded once
a day after the first 48 hours for the final 5 days.
Tissue
At the given time points, the animals were again anesthetized
with ketamine and xylazine. Serum and CSF samples were
obtained. After animals were killed, the left side of the chest
was reopened. The descending aorta was excised to confirm that
the crossclamp occluded the highest spinal artery. Any animal
clamped below this branch was excluded from the study, re-
gardless of group, because this critical spinal vessel can poten-
tially preserve blood flow to the spinal cord. Next, the lumbar
spinal cord was extracted to be fixed for histology and flash-
frozen for molecular studies.
mber 2004
emia
Reece et al Surgery for Acquired Cardiovascular Disease
A
CDTumor Necrosis Factor-
Lumbar spinal cord lysate was generated from a minimum of 5 mg
of tissue sample in Triton X-100 lysis buffer (Sigma-Aldrich Corp,
St Louis, Mo) by using a tissue homogenizer (Fisher Scientific Inter-
national, Pittsburgh, Pa). The lysis buffer consisted of 1% Triton
X-100, 20 mmol/L Tris (pH 7.4; Sigma-Aldrich), 150 mmol/L NaCl
(Sigma-Aldrich), 1 mmol/L ethylenediaminetetraacetic acid (Sigma-
Aldrich), leupeptin 2 g/mL (Roche Diagnostics Corp, Indianapolis,
Ind), pepstatin 0.7g/mL (Roche), chymostatin 100mol/L (Roche),
and antipain 100 mol/L (Roche). After centrifuging at 10,000 RPM
at 0°C for 10 minutes, the supernatant was aspirated and frozen.
Figure 1. Hind limb function in the Tarlov scale over the
**P < .01 compared with both sham and ATL. IR, Isch
Figure 2. Myeloperoxidase activity in spinal cord tissu
groups at 12, 24, and 48 hours of reperfusion. *P < .01
in absorbance.TNF- levels of spinal cord tissue lysates, CSF, and serum were
The Journal of Thoracidetermined by a commercially available enzyme-linked immunosor-
bent assay (ELISA) kit (Pierce Biotechnology Inc, Rockford, Ill)
according to the manufacturer’s protocols. All samples were tested in
duplicate and averaged. The ELISA kit sensitivity for TNF- was 20
pg/mL. All readings were performed on an MRX II absorbance reader
(DYNEX Technologies Inc, Chantilly, Va). The TNF- concentration
was expressed in picograms per milliliter.
Myeloperoxidase
Neutrophil sequestration in the spinal cord was quantified with a
48 hours of reperfusion. *P< .05 compared with sham;
/reperfusion.
ong the ATL-146e, sham, and ischemia/reperfusion (IR)
mpared with the sham and ATL groups. OD, Changefirste am
5 comyeloperoxidase (MPO) assay. Spinal cord tissue that had been
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resuspended in 50 mmol/L KPO4 (pH 7.4) and then homogenized
for 30 seconds at 4°C. The solution was centrifuged for 15 minutes
at 15,000g (Sorvall RC-5b Refrigerated Superseed Centrifuge;
Kendro Labor Products, Newton, Conn). The supernatant was
discarded. Next, the pellet was resuspended in 10 vol of 0.5%
hexadecyltrimethylammonium bromide (HTAB) in 50 mmol/L
KPO4 (pH 6.4) before a second homogenization of 90 seconds at
4°C. The solution underwent sonication and 3 freeze/thaw cycles
(liquid nitrogen and 37°C circulating bath). The solution was
centrifuged for a second time at 15,000g for 15 minutes. Then, 15
mL of supernatant was combined with 135 mL of assay buffer (10
mg of o-dianisidine in 1 mL of deionized water, 100 L of H2O2,
and 8.9 mL of 50 mmol/L KPO4 [pH 6.0]) incubated at room
temperature. Absorbance at 460 nm was measured over 2 minutes
by spectrophotometry (MRX Revelation Plate Reader; Dynex
Technologies, Inc, Chantilly, Va). Protein concentrations were deter-
mined in each sample by using the Coomassie Plus Protein Assay
(Bio-Rad, Hercules, Calif). MPO activity was then expressed as a
change in absorbance (OD) per milligram protein per minute.
Neuronal Viability
Five-micrometer sections of formalin-fixed samples were stained with
hematoxylin and eosin. Semiserial sections from the midthoracic
spinal cord were counted in blinded fashion for the number of viable
ventral horn motor neurons by using standard criteria. The mean
number of intact motor neurons was quantitated for comparison.
MAP-2 Immunohistochemistry
Ten-micrometer sections of formalin-fixed samples were mounted
on slides and deparaffinized in xylenes and progressive alcohol
rinses. In preparation for immunocytochemistry, sections were
processed by using a temperature-controlled microwave antigen-
retrieval approach described previously in detail.11 Endogenous
peroxidase was blocked by incubation in a solution of 1.65% H O
Figure 3. Spinal cord tumor necrosis factor (TNF)-
groups over the first 48 hours of reperfusion. *P < .012 2
in 0.025% Triton X in Tris-buffered saline (TBS). Sections were
928 The Journal of Thoracic and Cardiovascular Surgery ● Deceincubated overnight in mouse anti–MAP-2 antibody (clone MT-
01; Abcam Ltd, Cambridge, United Kingdom) at a dilution of
1:100 in TBS with 1% bovine serum albumin before they were
rinsed in TBS/Triton X and incubated for 2 hours in biotinylated
anti-mouse immunoglobulin G (1:200; Vector, Burlingame, Calif)
in TBS with 1% bovine serum albumin. After incubation in an
avidin-biotin-peroxidase complex (ABC standard Elite kit; Vector;
dilution of 1:100), and sections were processed for visualization of
the immunohistochemical complex by 0.05% diaminobenzidine
(Sigma-Aldrich) and 0.01% hydrogen peroxide.
The percentage of gray matter stained positively for MAP-2
within injured spinal cord was quantified and statistically com-
pared among treatment groups and control animals. Semiserial
spinal cord sections reacted for MAP-2 were examined with a
microscope interfaced with a charge-coupled device digital camera
and computer image analysis system (VisionGauge Image Analy-
sis software; VISIONx Inc, Pointe Claire, Quebec, Canada). Im-
ages of spinal cord sections were captured and digitized. Gray
matter was outlined in the VisionGauge system, and background
staining thresholds were calculated in adjacent white matter tissue
for each section. The percentage of gray matter tissue staining
positively above background thresholds were then calculated by
the VisionGauge software. The mean percentage of MAP-2 gray
matter staining was thus calculated for each animal.
Statistics
The statistics were analyzed by our statistician, who used analysis
of variance with Bonferroni multiple comparison tests to deter-
mine significant differences. A nonparametric analysis provided
the same conclusions as the analysis of variance.
Results
Hind Limb Function
Functional outcomes, quantified by Tarlov scores, showed a
g the ATL-146e, sham, and ischemia/reperfusion (IR)
pared with both sham and ATL.amontrend toward preservation in ATL compared with IR ani-
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and continued to be significant at 36 and 48 hours. Figure 1
depicts functional outcomes in the first 48 hours. The mean
Tarlov scores of the long-term survivors remained stable
over 7 days as follows: day 1, 4.25  0.48; day 2, 4.75 
0.25; day 3, 4.75  0.25; day 4, 4.75  0.25; day 5, 4.75 
0.25; day 6, 4.75  0.25; and day 7, 4.75  0.25.
Neutrophil Sequestration
The spinal cord MPO assay demonstrated no differences
Figure 4. Neuronal viability of spinal cord motor neuro
ATL-146e, sham, and ischemia/reperfusion (IR) groups o
both sham and ATL.
Figure 5. Microtubule-associated protein–2 (MAP-2) e
stained) over the first 48 hours of reperfusion. †P < .05
< .05 compared with IR.in neutrophil sequestration among groups at 12 hours. By
The Journal of Thoraci24 and 48 hours, however, the MPO was significantly
lower in sham and ATL animals compared with IR ani-
mals (Figure 2).
TNF-
Serum and CSF concentrations of TNF- remained below
the reliably detectable limits of the ELISA preparation.
Although a significantly different bimodal peak of TNF- in
these compartments was noted in the IR group, the impli-
cations of these findings can only be speculated at such low
iable neurons per high-powered field [hpf]) among the
e first 48 hours of reperfusion. *P< .05 compared with
ssion in gray matter (percentage area of gray matter
pared with both ATL and ischemia/reperfusion (IR); *Pns (v
ver thxpre
comlevels.
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centrations were similarly low at reperfusion and 3 hours
later among all 3 groups. By 6 hours after reperfusion,
spinal cord TNF- in sham and ATL animals remained low,
with significantly higher levels in IR animals. At 12 hours,
the spinal cord TNF- concentration leveled off in IR
animals, only to peak again at 24 hours in all 3 groups.
Neuronal Viability
Spinal cord tissue from sham animals demonstrated normal
gray and white matter cytoarchitecture, with large pyrami-
dal ventral horn motor nuclei and prominent nucleoli. Tis-
sue from ATL-treated animals demonstrated mild cytoar-
chitectural derangement, whereas IR animals had markedly
abnormal spinal cords with vacuolization of parenchyma
and multiple pyknotic neuronal somata.
Neuronal viability demonstrated no significant differ-
ences among groups at 12 hours of reperfusion. By 24 hours
of reperfusion, significantly fewer viable neurons per high-
power field were noted in IR animals compared with the
sham and ATL groups. By 48 hours of reperfusion, neuronal
viability deteriorated in the IR group compared with the
other 2 groups. Neuronal viability, assessed by neurons per
high-power field in ventral horn gray matter, in the first 48
hours is shown in Figure 4.
MAP-2 Immunohistochemistry
After 6 hours of reperfusion, the MAP-2 expression (percent-
age stained in gray matter) remained nearly identical among
the 3 groups. By 12 hours, IR animals had significantly less
MAP-2 expression compared with sham, but they were still not
different from the ATL animals. By 24 hours of reperfusion,
MAP-2 expression was significantly different among all 3
groups. At 48 hours, MAP-2 expression was again signifi-
cantly different among all 3 groups. MAP-2 expression in the
first 48 hours is shown in Figure 5.
Discussion
Various pharmacologic agents have been studied with the
goal of attenuating ischemic spinal cord injury, but their
utility in patients remains controversial.2 Improved under-
standing about injury progression and the role of inflamma-
tion in this process would permit the identification of novel
strategies to limit IR injury. Our laboratory has demon-
strated a potential therapeutic benefit of adenosine in this
context.10,12 However, adenosine requires a hypothermic
carrier and local delivery, which restricts its use.13
Improved understanding of the mechanism of action of
adenosine has elucidated the role of specific adenosine
receptors. Systemic adenosine A2A receptor activation has
attenuated injury in a rabbit model of spinal cord ischemia.7
This study demonstrates the attenuation of injury progres-
sion by adenosine A2A receptor activation from 3 different
930 The Journal of Thoracic and Cardiovascular Surgery ● Deceperspectives of IR injury in the spinal cord. Tarlov scores
were used to evaluate and follow up functional impairment.
Neuronal cytoarchitecture was observed by using both neu-
ronal viability scoring and the extent of MAP-2 expression.
Finally, inflammation was assessed both by observing
TNF- in systemic, regional, and local compartments and
by evaluating neutrophil sequestration in spinal cord tissue.
Evaluation of these variables over time provides important
insights into the interplay among these factors in both the
progression and prevention of spinal cord IR injury.
The trend toward functional preservation with ATL ther-
apy became statistically significant at 24 hours of reperfu-
sion, at which time both sham and ATL animals had higher
Tarlov scores than IR animals. This difference was sus-
tained at 48 hours after reperfusion. The ATL group ob-
served with longer evaluation preserved their 24-hour func-
tional scores through 7 days, indicating that no deterioration
of motor function arose subacutely among treated animals.
The study also demonstrated differences among groups
in the progression of cytoarchitectural injury. Although
differences in MAP-2 became notable by 12 hours after
reperfusion between 2 of the groups, the differences in
MAP-2 expression between the IR group and the other 2
groups did not become significant until 24 hours after reper-
fusion. By 48 hours after reperfusion, significant differences
arose among all 3 groups, including significant differences
between the sham group and the ATL group. Neuronal
viability became significant after 24 hours of reperfusion
between the IR group and the other 2 groups, and this
continued through 48 hours after reperfusion. These find-
ings demonstrate that histologic and immunohistochemical
evidence of injury is not immediate and is preceded by
detectable differences in motor functioning.
By comparing the inflammatory response to IR injury in
other organ systems with the results of this study, interesting
parallels are identified.14 Cassada and colleagues8 demon-
strated reduced serum TNF- concentrations by adenosine
A2A receptor activation after temporary aortic occlusion in
rabbits. The current study expanded on this finding by
evaluating local, regional, and systemic inflammatory re-
sponses to spinal cord IR injury. Our current study did not
demonstrate appreciable concentrations of TNF- in serum
or CSF to allow speculation about the systemic—or even
regional—inflammatory response to this injury. The higher
tissue concentrations showed a similar pattern that sug-
gested a bimodal release of TNF- after IR. Spinal cord
tissue from the IR group demonstrated a significant increase
in tissue TNF- by 6 hours of reperfusion compared with
the ATL and sham groups. Although IR spinal cord tissue
TNF- levels seemed to plateau after 12 hours of reperfu-
sion, by 24 hours after reperfusion, the level peaked at a
higher concentration in all 3 groups, which was significantly
higher in IR animals compared with ATL and sham animals.
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not predicted, but similar observations have been made at
earlier time points in pulmonary IR injury.15-17 These stud-
ies concluded that the resident macrophages were responsi-
ble for early inflammation, which is followed with more
vigor by the neutrophil response to the IR injury. Because
the spinal cord harbors no resident leukocytes, the early
peak in tissue TNF- in our study may derive from
microglia, which precipitate the neutrophil response and
lead to amplification of inflammation after 24 hours of
reperfusion. This did coincide with the significant in-
crease in neutrophil sequestration in the IR group. This
finding supports the conclusion from other organ models
of IR that describe early local cellular inflammation
trailed by a later, more intense neutrophil-derived inflam-
matory response.
This study demonstrated that ATL-146e attenuated the
inflammatory response to IR in the spinal cord, but it did not
identify the attenuating mechanism. The study demon-
strated both inflammatory attenuation and functional pres-
ervation, but the exact relationship between the 2 remains
unknown. The study does not exclude the possibility that
inflammation is impaired by adenosine A2A receptor acti-
vation because of direct neuroprotective effects that limit
initial spinal cord neuronal injury. Other authors have ar-
gued that early intervention remains the best chance for
functional preservation after spinal cord injury in both vas-
cular surgery and blunt spinal cord trauma.18 The benefit of
pharmacologic protection with ATL-146e may be optimized
with the initiation of therapy at reperfusion. Preventive
strategies are already being exploited with lumbar CSF
drainage, regional cooling, and distal perfusion tech-
niques.19-21 ATL-146e clearly preserves spinal cord func-
tion and neuronal cytoarchitecture and attenuates the in-
flammatory response after IR. The protective mechanisms
are not fully understood, but animals maintain function
despite ischemic insult.
In conclusion, this study demonstrated optimal time
points for studies of differences in function, inflammation,
and neuronal cytoarchitecture. Most notably in this study
and in patients undergoing transient thoracic aortic occlu-
sion who might avoid distal bypass or lumbar drain
placement, adenosine A2A receptor activation attenuates
every aspect of injury measured, including markers of
hind limb function, neuronal cytoarchitecture, and in-
flammation.
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Dr Robert C. Robbins (Stanford, Calif). Can you tell me what
these animals look like? I am not familiar with this Tarlov score,
so can these pigs walk, or are they a little bit weaker than the
others?
Dr Reece. The Tarlov score ranges from 0 to 5. So 0 means
complete hind limb paralysis; 1 indicates some hind limb move-
ment; 2 means that the animal can sit when placed in a sitting
position; 3 means that it can sit without assistance; 4 indicates an
unsteady gait; and 5 indicates a normal gait.
Dr Ross M. Ungerleider (Portland, Ore). Let me just be clear
about this. You had a 30-minute ligation, or ischemic injury?
Dr Reece. Yes, sir.
Dr Ungerleider. And ATL was given before that, 10 minutes
before and then for 3 hours?
Dr Reece. Correct.
Dr Ungerleider. Are you postulating that there is some sort of
inflammatory process that is caused by the ischemic injury and that
this is the mechanism?
Dr Reece. I think that if you had asked me that when we started
working with ATl-146e, I would have agreed wholeheartedly that
inflammatory inhibition was the mechanism of protection from
ischemic injury in this model. However, the more that we learn
about this compound, the more it seems that we are attenuating the
injury directly. This study in particular demonstrates that none of
the inflammatory markers is actually becoming significantly dif-
ferent until after the function has been altered by the injury. So we932 The Journal of Thoracic and Cardiovascular Surgery ● Decethen an inflammatory response to the injury itself which is also
attenuated.
Dr Robbins. Where does this compound stand in develop-
ment? Is it being given clinically for any other indication?
Dr Reece. Right now it is being given in patients for coronary
angiography at much higher doses, but we have not yet used it for
injury attenuation in patients.
Dr Robbins. If it is available to be used in patients with aortic
surgery, do you have any plans to do a clinical study using this?
Dr Reece. We are pursuing a clinical study, but we are pushing
to study ATL-146e in patients who have sustained blunt spinal
trauma, to recruit a higher volume of patients and with more
statistical potential for injury attenuation.
Dr Ungerleider. I presume that your hemodynamics of the
animals are the same in all groups: temperatures are the same?
Dr Reece. Correct. The temperatures were monitored with a
rectal probe and adjusted with a heating pad. We have never seen
any hemodynamic differences with this dosage of ATL-146e in
any of our models of ischemia/reperfusion injury.
Dr Carmelo A. Milano (Durham, NC). I was going to ask the
same thing Ross just mentioned. I think that when you present
these data, it is important to show the hemodynamics, because this
is a potentially hemodynamically significant agent that you are
giving, and during the period of ischemia there is presumably some
limited collateral perfusion. So when you show the data, I think it
is important to document or to demonstrate that the hemodynamics
are equivalent in the 2 groups, because that will certainly affect thewould postulate that we are attenuating the injury and that there is collateral circulation.mber 2004
